The differences of physiology, fluid parameters and core structures of thrombus in artery and
vein determine the distinct ways for arterial and venous thrombolytic treatments. As an …

Thrombotic diseases have a high rate of mortality and disability, and pose a serious threat to
global public health. Currently, most thrombolytic drugs especially protein drugs have a …

We report the construction of blood cell membrane cloaked mesoporous silica nanoparticles
for delivery of nanoparticles [fullerenols (Fols)] with fibrinolysis activity which endows the …

Rapid cut‐off of blood supply in diseases involving thrombosis is a major cause of morbidity
and mortality worldwide. However, the current thrombolysis strategies offer limited results …

In recent years, the fabrication of nano-drug delivery systems for targeted treatment of
thrombus has become a research hotspot. In this study, we intend to construct a biomimetic …

The treatment difficulties of venous thrombosis include short half-life, low utilization, and
poor penetration of drugs at thrombus site. Here, we develop one kind of mesoporous …

Due to the high morbidity and mortality of cardiovascular diseases, there is an urgent need
for research on antithrombotic strategies. In view of the short half-life, insufficient drug …

Lower extremity deep venous thrombosis (LEDVT) affects patient's quality of life for a long
time, and even causes pulmonary embolism, which threatens human health. Current …

Thrombus related diseases seriously threaten human's health and life. The drawbacks of
thrombolytic drugs, such as poor targeting ability and unexpected bleeding complications …

Thrombotic disease has been listed as the third most fatal vascular disease in the world.
After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of …